Arrowhead Pharmaceuticals, Inc.
Records under this name other than the patents Arrowhead Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 138 patents it holds.
Back to Arrowhead Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,868,949 | Organic Compositions to Treat EPAS1-RELATED Diseases Formerly held In force · High confidence | In force | High confidence | |
| US 9,040,494 | Rnai-Mediated Inhibition of Frizzled Related PROTEIN-1 for Treatment of Glaucoma Term ended Term ended Nov 7, 2026 · High confidence | Term ended | Term ended Nov 7, 2026 | High confidence |
| US 8,865,670 | Rnai-Related Inhibition of Tnfa Signaling Pathway for Treatment of Glaucoma Lapsed on the fee record Ended Oct 21, 2026 · Low confidence | Lapsed on the fee record | Ended Oct 21, 2026 | Low confidence |
| US 8,865,671 | RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions Lapsed on the fee record Ended Oct 21, 2026 · Low confidence | Lapsed on the fee record | Ended Oct 21, 2026 | Low confidence |
| US 10,081,811 | Organic Compositions to Treat Beta-Enac-Related Diseases Lapsed on the fee record Ended Sep 25, 2026 · High confidence | Lapsed on the fee record | Ended Sep 25, 2026 | High confidence |
| US 8,754,202 | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS Lapsed on the fee record Ended Jun 17, 2026 · Medium confidence | Lapsed on the fee record | Ended Jun 17, 2026 | Medium confidence |
| US 9,938,531 | Compositions and Methods for Inhibiting Expression of RRM2 Genes Lapsed on the fee record Ended Apr 10, 2026 · High confidence | Lapsed on the fee record | Ended Apr 10, 2026 | High confidence |
| US 9,932,584 | Interfering RNA Delivery System and Uses Thereof Lapsed on the fee record Ended Apr 3, 2026 · Medium confidence | Lapsed on the fee record | Ended Apr 3, 2026 | Medium confidence |
| US 8,673,873 | RNAi-Mediated Inhibition of Phosphodiesterase Type 4 for Treatment of cAMP-Related Ocular Disorders Lapsed on the fee record Ended Mar 18, 2026 · Medium confidence | Lapsed on the fee record | Ended Mar 18, 2026 | Medium confidence |
| US 8,173,617 | Rnai-Mediated Inhibition of Frizzled Related PROTEIN-1 for Treatment of Glaucoma Term ended Term ended Mar 10, 2026 · High confidence | Term ended | Term ended Mar 10, 2026 | High confidence |